Tag archive

Dayvigo

Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan

in Pharmaceutical News
Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan

Eisai Co., Ltd. announced today that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia. DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). Blocking the binding of wake-promoting neuropeptides orexin to orexin receptors is thought to suppress wake drive by balancing sleep-wake…

Keep Reading

Go to Top